Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus penpulimab for EGFR-mutant advanced non-squamous NSCLC after EGFR-TKI failure
ChiCTR2300075255Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and penpulimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: progression-free survival. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300075255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075255.